July 11, 2003
Schering AG, the world's biggest maker of birth-control pills, said a brightening agent used to show blood flow in magnetic resonance imaging boosted the test's ability to find kidney disease and circulatory disorders.
Trials from the last of three phases of clinical studies on imaging agent MS-325 showed ``statistically significant'' improvement in the accuracy of the MRI tests, Berlin-based Schering said. It's developing the agent with Epix Medical Inc. of Cambridge, Massachusetts.
Schering, which has 60 percent of the global market for MRI agents, expects peak potential annual sales of the agent of 100 million euros ($113 million), spokesman Friedrich von Heyl said. It aims to introduce the drug in the U.S. in 2005, and in Europe in 2005 or 2006.
The company's second-biggest-selling product, after the multiple sclerosis drug Betaseron, is the MRI agent Magnevist, which posted 2002 sales of 322 million euros.
Schering shares rose 95 cents, or 2.2 percent, to 43.92 euros at 10:53
a.m. in Frankfurt. The stock has dropped 6 percent this year.
Copyright © 2003, Bloomberg L.P.